Progress in drug development of immunostimulatory CpG oligodeoxynucleotide ligands for TLR9.
about
Vaccination for hepatitis C virus: closing in on an evasive targetProphylactic application of CpG oligonucleotides augments the early host response and confers protection in acute melioidosisAiming to induce broadly reactive neutralizing antibody responses with HIV-1 vaccine candidatesFunctional interaction of plasmacytoid dendritic cells with multiple myeloma cells: a therapeutic target.Activation of innate immunity in healthy Macaca mulatta macaques by a single subcutaneous dose of GMP CpG 7909: safety data and interferon-inducible protein-10 kinetics for humans and macaquesMG7 mimotope-based DNA vaccination for gastric cancer.Strategies of mucosal immunotherapy for allergic diseasesCpG oligodeoxyribonucleotides protect mice from Burkholderia pseudomallei but not Francisella tularensis Schu S4 aerosols.A novel TLR-9 agonist C792 inhibits plasmacytoid dendritic cell-induced myeloma cell growth and enhance cytotoxicity of bortezomib.Glutathione and Bcl-2 targeting facilitates elimination by chemoradiotherapy of human A375 melanoma xenografts overexpressing bcl-xl, bcl-2, and mcl-1NOD2 regulation of Toll-like receptor responses and the pathogenesis of Crohn's diseaseEnhancement of humoral immunity in mice by coupling pUCpGs10 and aluminium to the HCV recombinant immunogen.Tumor vaccines for breast cancerAntisense- and RNA interference-based therapeutic strategies in allergy.TLR9 in health and disease.Toll-like receptor modulation in cardiovascular disease: a target for intervention?Aiming to induce broadly reactive neutralizing antibody responses with HIV-1 vaccine candidates.The effect of CpG-oligodeoxynucleotides with different backbone structures and 3' hexameric deoxyriboguanosine run conjugation on the treatment of asthma in mice.IRAK-M alters the polarity of macrophages to facilitate the survival of Mycobacterium tuberculosis.Innate immune defenses induced by CpG do not promote vaccine-induced protection against foot-and-mouth disease virus in pigs.CpG7909 adjuvant enhanced immunogenicity efficacy in mice immunized with ESAT6-Ag85A fusion protein, but does not confer significant protection against Mycobacterium tuberculosis infection.Synthetic Poly(L-Glutamic Acid)-conjugated CpG Exhibits Antitumor Efficacy With Increased Retention in Tumor and Draining Lymph Nodes After Intratumoral Injection in a Mouse Model of Melanoma.Phosphatidylinositol-3-kinase activity during in vitro dendritic cell generation determines suppressive or stimulatory capacity.
P2860
Q22305922-84EAF66E-1333-4BD2-A748-263156C02605Q27305350-43A5ECC7-706C-4AFA-9CFE-DDB512B3B5D5Q27489000-326C9663-6376-4BE4-AC1B-94D24924D4F3Q30490975-E03BC9FB-1732-4089-AE48-BEC086287768Q31139969-B2B19DA5-D153-4E9B-BF5F-F9005D763013Q33239626-CC495EF6-72BE-436B-A650-E831AA1A04ADQ33577679-7C36D621-C87F-4C34-83D3-99F28DE4A141Q33698285-66383DB2-48A3-47F1-B1D4-8D5B24DC8CB1Q33976734-A08A3B54-9500-4688-B784-FDF3F8B3E56EQ34123184-CD976CC2-FC04-48C6-80E2-061A8B9F1E54Q35597934-663FDF34-48DE-4CF9-921B-DAE13C227EEAQ35682493-00985369-2703-4FA6-BABB-484A01840B00Q36204803-BD536D32-D319-4BA7-9D63-8DC8A52C9463Q36346493-5F222522-9C39-41B5-90A8-C37614441029Q36526346-FD42C467-95EA-4459-8FC7-6E487A9846E8Q36543054-9626D597-F4ED-4FA1-92B8-E2834B4DA8EBQ36600380-E3C60E6D-28FF-494E-8677-C449011A41C7Q37364531-ECADE86B-3A2F-4DC7-B11E-31E3745D9EBEQ40082215-C48EDEC4-021E-4C81-B6A1-B0795ECDC9D4Q41827099-F19C3810-FBF7-4BAE-8609-67671661B90CQ47891655-7DCC3760-5EDC-4423-BDFE-22BE5D0CFBA0Q49202561-B7873358-8A1C-418D-B7FB-B52AA36D634FQ53255338-06DB3271-06F6-44E1-979A-AB5F54A1FC1B
P2860
Progress in drug development of immunostimulatory CpG oligodeoxynucleotide ligands for TLR9.
description
2005 nî lūn-bûn
@nan
2005年の論文
@ja
2005年論文
@yue
2005年論文
@zh-hant
2005年論文
@zh-hk
2005年論文
@zh-mo
2005年論文
@zh-tw
2005年论文
@wuu
2005年论文
@zh
2005年论文
@zh-cn
name
Progress in drug development o ...... xynucleotide ligands for TLR9.
@ast
Progress in drug development o ...... xynucleotide ligands for TLR9.
@en
type
label
Progress in drug development o ...... xynucleotide ligands for TLR9.
@ast
Progress in drug development o ...... xynucleotide ligands for TLR9.
@en
prefLabel
Progress in drug development o ...... xynucleotide ligands for TLR9.
@ast
Progress in drug development o ...... xynucleotide ligands for TLR9.
@en
P2860
P356
P1476
Progress in drug development o ...... xynucleotide ligands for TLR9.
@en
P2093
Jörg Vollmer
P2860
P304
P356
10.1517/14712598.5.5.673
P407
P577
2005-05-01T00:00:00Z